|
- Pharmaceutical Research Development | AbbVie
AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives
- AbbVie Reports Second-Quarter 2025 Financial Results | AbbVie
AbbVie and Capstan Therapeutics, a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using targeted lipid nanoparticles (tLNPs), announced a definitive agreement under which AbbVie will acquire Capstan The transaction includes CPTX2309, a potential first-in-class in vivo tLNP anti
- Our Company - AbbVie
At AbbVie, we combine advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives See how we’re improving health care on a global basis
- AbbVie News Center - News
AbbVie Submits for U S FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
- AbbVie lifts outlook amid acquisitions, key drug gains | Crains . . .
AbbVie raised adjusted diluted earnings per share from a range of $11 67 to $11 87 up to a range of $11 87 to $11 88, despite the acquired IPR D and milestone expenses in the first half of this
- Welcome to AbbVie
If you are a resident of a country other than those to which the site is directed, please return to AbbVie com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence
- Investor Overview | AbbVie
AbbVie is a global biopharmaceutical company with focus and capabilities to address some of the world's greatest health challenges
- About AbbVie - Abbvie Clinical Trials
Learn about AbbVie and our unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases
|
|
|